Concepedia

Publication | Open Access

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

DOIFull Paper Access

94

Citations

37

References

2010

Year

B. Douglas Smith, Yvette L. Kasamon, Jeanne Kowalski, Christopher D. Gocke, Kathleen M. Murphy, Carole B. Miller, Elizabeth Garrett‐Mayer, Hua-Ling Tsai, Qin Lu, Christina Y. Chia,
Clinical Cancer Research

Abstract

K562/GM-CSF vaccine appears to improve molecular responses in patients on imatinib mesylate, including achieving complete molecular remissions, despite long durations of previous imatinib mesylate therapy.

References

YearCitations

Page 1